Biomarkers for immunotherapy response in head and neck cancer.

By N. Gavrielatou, S. Doumas, P. Economopoulou, P. Foukas, A. Psyrri. 2020

Subfields: Oncology, Otorhinolaryngology

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Regarding the clinical approval of the aforementioned antibodies by federal agencies, prognostic indicators such as a tumor proportion score (TPS) > 50% and a combined positive score (CPS) ≥ 1 have been identified for predicting a good immunotherapeutic response [8].”